Elyxium Wealth’s Summit Therapeutics SMMT Stock Holding History

Elyxium Wealth’s Portfolio SMMT Stock Details SMMT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$355	Buy	+21	New	+$314	﹤0.01%	1425

Other funds holding SMMT

Simplify Asset Management Las Vegas, Nevada $6.11B AUM 3.71% 1-Year Est. Return

Griffin Asset Management New York $934M AUM 18.69% 1-Year Est. Return

Tema ETFs New York $2.69B AUM 42.96% 1-Year Est. Return

Wealth Management Partners Tucson, Arizona $426M AUM 43.17% 1-Year Est. Return

Wealth Enhancement Advisory Services Plymouth, Minnesota $67.3B AUM 21.9% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return

Y-Intercept (HK) Hong Kong $4.52B AUM 6.6% 1-Year Est. Return

Inspire Investing Meridian, Idaho $2.37B AUM 29.82% 1-Year Est. Return

Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return

Kingswood Wealth Advisors San Diego, California $2.6B AUM 27.46% 1-Year Est. Return

Elyxium Wealth's SMMT Position: Q3 2026 in Review

Elyxium Wealth opened a new position in Summit Therapeutics (SMMT) in Q3 2026: 21 shares worth $355. The stake represents ﹤0.01% of the portfolio and ranks #1425 among its holdings.

48 funds tracked by Wall St. Rank hold SMMT as of Q3 2026.

Elyxium Wealth held 21 shares of Summit Therapeutics worth $355 as of Q3 2026.
Summit Therapeutics was a new Elyxium Wealth position in Q3 2026.
Summit Therapeutics made up ﹤0.01% of Elyxium Wealth's portfolio in Q3 2026, its #1425 holding.
48 funds tracked by Wall St. Rank held Summit Therapeutics as of Q3 2026.

Based on Elyxium Wealth's 13F filing for Q3 2026, filed 27 Oct 2026.